Member

PHIOGEN Inc.


PHIOGEN is a preclinical-stage biotechnology company developing bacteriophage-based approaches for drug-resistant and recurrent bacterial infections. Its development work combines phage discovery and selection, directed evolution, human-relevant infection models, formulation, and preclinical testing. The company is also exploring immune responses associated with phage therapy.

Industries

N/A

PHIOGEN Inc.

1840 Dynamic Way, Rm 270, Houston, Texas 77030, USA

PHIOGEN Inc. is currently seeking investment

PHIOGEN Inc. is seeking a series-a investment in the range of

All Investment-seeking Members

Expertise Areas

  • Bacteriophage therapeutics
  • Antimicrobial-resistant bacterial infections
  • Phage biology and evolution
  • Bacterial pathogenesis
  • Show More (3)

Key Technologies

  • Bacteriophage isolation and screening
  • Genome sequencing and annotation
  • Directed evolution
  • Stem-cell-derived 3D culture models
  • Show More (3)

Key People

Chief Executive Officer

Clinical Operations Manager

Bioinformaticist

Head of Finance

Associate Scientist

Associate Scientist

View All People

News & Updates

PHIOGEN was named among the Top 10 Most Promising Life Science Companies at the Texas Life Science Forum.

PHIOGEN, Baylor College of Medicine, and LillixBio announced a collaboration using AI-supported antigen mapping and laboratory validation to study immune responses following phage therapy, initially targeting E. coli.

PHIOGEN announced support from CARB-X for a project targeting E. coli infections using bacteriophages.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.